Total Payments
$1,991
2024 Payments
$219.84
Companies
17
Transactions
102
Medicare Patients
973
Medicare Billing
$83,461
Payment Breakdown by Category
Food & Beverage$1,984 (99.7%)
Education$6.95 (0.3%)
Other$0.00 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $1,984 | 101 | 99.7% |
| Education | $6.95 | 1 | 0.3% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Novo Nordisk Inc | $461.16 | 27 | $0 (2024) |
| AstraZeneca Pharmaceuticals LP | $309.44 | 17 | $0 (2024) |
| GlaxoSmithKline, LLC. | $227.59 | 13 | $0 (2023) |
| Amgen Inc. | $201.74 | 6 | $0 (2018) |
| Lilly USA, LLC | $148.64 | 9 | $0 (2024) |
| PFIZER INC. | $141.41 | 7 | $0 (2024) |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $121.66 | 6 | $0 (2024) |
| Gilead Sciences, Inc. | $120.21 | 1 | $0 (2018) |
| Merck Sharp & Dohme Corporation | $52.04 | 4 | $0 (2017) |
| Exact Sciences Corporation | $46.25 | 3 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $219.84 | 13 | Novo Nordisk Inc ($74.43) |
| 2023 | $358.39 | 20 | AstraZeneca Pharmaceuticals LP ($97.47) |
| 2022 | $33.23 | 2 | Novo Nordisk Inc ($18.65) |
| 2021 | $79.62 | 1 | AstraZeneca Pharmaceuticals LP ($79.62) |
| 2018 | $347.34 | 14 | Gilead Sciences, Inc. ($120.21) |
| 2017 | $952.72 | 52 | Novo Nordisk Inc ($249.12) |
All Payment Transactions
102 individual payment records from CMS Open Payments — Page 1 of 5
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 07/16/2024 | Novo Nordisk Inc | — | Food and Beverage | In-kind items and services | $18.56 | General |
| 06/19/2024 | Lilly USA, LLC | MOUNJARO (Drug), ZEPBOUND | Food and Beverage | In-kind items and services | $15.04 | General |
| Category: Diabetes | ||||||
| 06/11/2024 | Novo Nordisk Inc | — | Food and Beverage | In-kind items and services | $17.14 | General |
| 05/27/2024 | AstraZeneca Pharmaceuticals LP | BREZTRI (Drug) | Food and Beverage | In-kind items and services | $16.64 | General |
| Category: Respiratory | ||||||
| 05/14/2024 | Novo Nordisk Inc | — | Food and Beverage | In-kind items and services | $16.07 | General |
| 04/29/2024 | Lilly USA, LLC | MOUNJARO (Drug), ZEPBOUND | Food and Beverage | In-kind items and services | $14.08 | General |
| Category: Diabetes | ||||||
| 04/09/2024 | Novo Nordisk Inc | — | Food and Beverage | In-kind items and services | $22.66 | General |
| 04/09/2024 | Exact Sciences Corporation | Cologuard Collection Kit (Device) | Food and Beverage | In-kind items and services | $13.52 | General |
| Category: Oncology | ||||||
| 04/01/2024 | AstraZeneca Pharmaceuticals LP | BREZTRI (Drug) | Food and Beverage | In-kind items and services | $15.09 | General |
| Category: Respiratory | ||||||
| 03/21/2024 | PFIZER INC. | ELIQUIS (Drug), PAXLOVID | Food and Beverage | In-kind items and services | $20.53 | General |
| Category: CARDIOVASCULAR;METABOLIC DISEASE | ||||||
| 02/13/2024 | Exact Sciences Corporation | Cologuard Collection Kit (Device) | Food and Beverage | In-kind items and services | $18.11 | General |
| Category: Oncology | ||||||
| 02/13/2024 | AstraZeneca Pharmaceuticals LP | BREZTRI (Drug) | Food and Beverage | In-kind items and services | $17.71 | General |
| Category: Respiratory | ||||||
| 02/09/2024 | Boehringer Ingelheim Pharmaceuticals, Inc. | JARDIANCE (Drug) | Food and Beverage | In-kind items and services | $14.69 | General |
| Category: DIABETES | ||||||
| 08/23/2023 | Novo Nordisk Inc | Ozempic (Drug), Rybelsus | Food and Beverage | In-kind items and services | $13.42 | General |
| Category: Diabetes | ||||||
| 08/21/2023 | AstraZeneca Pharmaceuticals LP | FARXIGA (Drug) | Food and Beverage | In-kind items and services | $20.60 | General |
| Category: Cardiovascular and Metabolism | ||||||
| 08/09/2023 | GlaxoSmithKline, LLC. | AREXVY (Drug), SHINGRIX | Food and Beverage | In-kind items and services | $17.97 | General |
| Category: RESPIRATORY | ||||||
| 08/07/2023 | Lilly USA, LLC | MOUNJARO (Drug) | Food and Beverage | In-kind items and services | $14.83 | General |
| Category: Diabetes | ||||||
| 06/30/2023 | Novo Nordisk Inc | — | Food and Beverage | In-kind items and services | $15.52 | General |
| 06/29/2023 | Boehringer Ingelheim Pharmaceuticals, Inc. | — | Food and Beverage | In-kind items and services | $25.20 | General |
| 06/22/2023 | AstraZeneca Pharmaceuticals LP | FARXIGA (Drug) | Food and Beverage | In-kind items and services | $16.96 | General |
| Category: Cardiovascular and Metabolism | ||||||
| 06/16/2023 | PFIZER INC. | PREVNAR 20 (Biological), COMIRNATY, PAXLOVID | Food and Beverage | In-kind items and services | $27.82 | General |
| Category: VACCINES | ||||||
| 06/06/2023 | PFIZER INC. | ELIQUIS (Drug), COMIRNATY, PAXLOVID | Food and Beverage | In-kind items and services | $21.93 | General |
| Category: CARDIOVASCULAR;METABOLIC DISEASE | ||||||
| 05/31/2023 | AstraZeneca Pharmaceuticals LP | BREZTRI (Drug) | Food and Beverage | In-kind items and services | $13.66 | General |
| Category: Respiratory | ||||||
| 05/30/2023 | Lilly USA, LLC | MOUNJARO (Drug) | Food and Beverage | In-kind items and services | $14.83 | General |
| Category: Diabetes | ||||||
| 05/24/2023 | GlaxoSmithKline, LLC. | AREXVY (Drug), SHINGRIX | Food and Beverage | In-kind items and services | $16.68 | General |
| Category: RESPIRATORY | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 4 | 197 | 234 | $53,240 | $20,924 |
| 2022 | 6 | 167 | 179 | $32,362 | $14,621 |
| 2021 | 6 | 288 | 317 | $55,599 | $24,632 |
| 2020 | 8 | 321 | 359 | $59,879 | $23,285 |
Total Patients
973
Total Services
1,089
Medicare Billing
$83,461
Procedure Codes
24
All Medicare Procedures & Services
24 procedure records from CMS Medicare Utilization
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| G0439 | Annual wellness visit, includes a personalized prevention plan of service (pps), subsequent visit | Office | 2023 | 82 | 82 | $20,766 | $10,489 | 50.5% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 75 | 106 | $26,322 | $8,452 | 32.1% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 23 | 29 | $4,928 | $1,462 | 29.7% |
| G0008 | Administration of influenza virus vaccine | Office | 2023 | 17 | 17 | $1,224 | $520.71 | 42.5% |
| G0439 | Annual wellness visit, includes a personalized prevention plan of service (pps), subsequent visit | Office | 2022 | 49 | 49 | $11,711 | $6,452 | 55.1% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 54 | 66 | $14,652 | $5,013 | 34.2% |
| 99497 | Advance care planning, first 30 minutes | Office | 2022 | 12 | 12 | $2,088 | $1,005 | 48.2% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 13 | 13 | $1,976 | $954.27 | 48.3% |
| 90674 | Influenza vaccine, quadrivalent derived from cell cultures, preservative and antibiotic free | Office | 2022 | 19 | 19 | $1,235 | $600.97 | 48.7% |
| G0008 | Administration of influenza virus vaccine | Office | 2022 | 20 | 20 | $700.00 | $595.80 | 85.1% |
| G0439 | Annual wellness visit, includes a personalized prevention plan of service (pps), subsequent visit | Office | 2021 | 97 | 97 | $23,183 | $13,286 | 57.3% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Office | 2021 | 79 | 101 | $22,422 | $6,810 | 30.4% |
| 99213 | Established patient outpatient visit, total time 20-29 minutes | Office | 2021 | 38 | 45 | $6,840 | $2,982 | 43.6% |
| G0444 | Annual depression screening, 15 minutes | Office | 2021 | 38 | 38 | $1,444 | $701.04 | 48.5% |
| 90674 | Vaccine for influenza derived from cell cultures for administration into muscle, 0.5 ml dosage, quadrivalent, , preservative and antibiotic free | Office | 2021 | 18 | 18 | $1,080 | $538.92 | 49.9% |
| G0008 | Administration of influenza virus vaccine | Office | 2021 | 18 | 18 | $630.00 | $313.74 | 49.8% |
| G0439 | Annual wellness visit, includes a personalized prevention plan of service (pps), subsequent visit | Office | 2020 | 109 | 109 | $26,051 | $13,005 | 49.9% |
| 99214 | Established patient office or other outpatient, visit typically 25 minutes | Office | 2020 | 73 | 92 | $20,424 | $5,529 | 27.1% |
| 99213 | Established patient office or other outpatient visit, typically 15 minutes | Office | 2020 | 51 | 59 | $8,968 | $2,758 | 30.7% |
| G0446 | Annual, face-to-face intensive behavioral therapy for cardiovascular disease, individual, 15 minutes | Office | 2020 | 26 | 26 | $1,404 | $705.86 | 50.3% |
| 90674 | Vaccine for influenza for administration into muscle, 0.5 ml dosage | Office | 2020 | 17 | 18 | $1,056 | $521.16 | 49.4% |
| G0008 | Administration of influenza virus vaccine | Office | 2020 | 17 | 18 | $630.00 | $306.78 | 48.7% |
| G0444 | Annual depression screening, 15 minutes | Office | 2020 | 17 | 17 | $646.00 | $282.67 | 43.8% |
| 96372 | Injection beneath the skin or into muscle for therapy, diagnosis, or prevention | Office | 2020 | 11 | 20 | $700.00 | $176.91 | 25.3% |
About Dr. Lara Wenner, MD
Dr. Lara Wenner, MD is a Family Medicine healthcare provider based in N Las Vegas, Nevada. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 09/20/2006. The National Provider Identifier (NPI) number assigned to this provider is 1164529350.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Lara Wenner, MD has received a total of $1,991 in payments from pharmaceutical and medical device companies, with $219.84 received in 2024. These payments were reported across 102 transactions from 17 companies. The most common payment nature is "Food and Beverage" ($1,984).
As a Medicare-enrolled provider, Wenner has provided services to 973 Medicare beneficiaries, totaling 1,089 services with total Medicare billing of $83,461. Data is available for 4 years (2020–2023), covering 24 distinct procedure/service records.
Ad
Practice Information
- Specialty Family Medicine
- Location N Las Vegas, NV
- Active Since 09/20/2006
- Last Updated 10/20/2022
- Taxonomy Code 207Q00000X
- Entity Type Individual
- NPI Number 1164529350
Products in Payments
- Tresiba (Drug) $181.86
- Prolia (Biological) $176.84
- FARXIGA (Drug) $173.57
- BREZTRI (Drug) $77.90
- ANORO (Drug) $63.89
- MOUNJARO (Drug) $58.78
- PREVNAR 20 (Biological) $55.94
- TRADJENTA (Drug) $53.74
- JARDIANCE (Drug) $51.88
- BREO (Drug) $51.62
- Cologuard Collection Kit (Device) $46.25
- Saxenda (Drug) $45.52
- Victoza (Drug) $45.20
- ELIQUIS (Drug) $42.46
- TRULICITY (Drug) $36.12
- AREXVY (Drug) $34.65
- SYMBICORT (Drug) $34.08
- Ozempic (Drug) $31.78
- XARELTO (Drug) $28.57
- Levemir (Drug) $28.22
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Family Medicine Doctors in N Las Vegas
William Jacks, Md, MD
Family Medicine — Payments: $16,485
Family Medicine $16,485
Dr. Binh Tran, Md, MD
Family Medicine — Payments: $13,281
Family Medicine $13,281
Jeaniene Talley, Md, MD
Family Medicine — Payments: $3,204
Family Medicine $3,204
Mohammad Atif, Md, MD
Family Medicine — Payments: $1,851
Family Medicine $1,851
Peter Asafo-Adjei, M.d, M.D
Family Medicine — Payments: $749.28
Family Medicine $749.28
Dr. Zephyrene Villaluz, M.d, M.D
Family Medicine — Payments: $187.91
Family Medicine $187.91